PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 21, 2025Biomedicines24 citationsOpen Access

Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery

View Full Paper
SOSherifdeen OnigbindeTexas Tech UniversityMAMoyinoluwa AdeniyiTexas Tech UniversityODOluwatosin DaramolaTexas Tech University

Key Points

  • Aberrant glycosylation is recognized as a key factor in various diseases, including cancer and autoimmune disorders.
  • The review emphasizes tumor-associated carbohydrate antigens as promising candidates for biomarker development in precision medicine.
  • Mass spectrometry and glycoengineering methods enable high-resolution profiling of the glycome, providing insights into disease mechanisms.
  • Understanding the glycome's dynamic regulation is crucial for developing innovative diagnostic and therapeutic strategies.

Abstract

Glycosylation, the enzymatic addition of glycans to proteins and lipids, is a critical post-translational modification that influences protein folding, stability, trafficking, immune modulation, and cell signaling. The vast structural diversity of glycans arising from differences in monosaccharide composition, branching, and terminal modifications such as sialylation, fucosylation, and sulfation underpins their functional specificity and regulatory capacity. This review provides a comprehensive overview of glycan biosynthesis, with a focus on N-glycans, O-glycans, glycosaminoglycans (GAGs), and glycolipids. It explores their essential roles in maintaining cellular homeostasis, development, and immune surveillance. In health, glycans mediate cell–cell communication, protein interactions, and immune responses. In disease, however, aberrant glycosylation is increasingly recognized as a hallmark of numerous pathological conditions, including cancer, neurodegenerative disorders, autoimmune diseases, and a wide range of infectious diseases. Glycomic alterations contribute to tumor progression, immune evasion, therapy resistance, neuroinflammation, and synaptic dysfunction. Tumor-associated carbohydrate antigens (TACAs) and disease-specific glycoforms present novel opportunities for biomarker discovery and therapeutic targeting. Moreover, glycan-mediated host–pathogen interactions are central to microbial adhesion, immune escape, and virulence. This review highlights current advances in glycomics technologies, including mass spectrometry, lectin microarrays, and glycoengineering, which have enabled the high-resolution profiling of the glycome. It also highlights the emerging potential of single-cell glycomics and multi-omics integration in precision medicine. Understanding glycome and its dynamic regulation is essential for uncovering the molecular mechanisms of disease and translating glycomic insights into innovative diagnostic and therapeutic strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Onigbinde et al. (2025) studied this question.

synapsesocial.com/papers/68af4ec6ad7bf08b1ead819bhttps://doi.org/10.3390/biomedicines13082034
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glycan-mediated modulation of cancer metastasis: Mechanisms and therapeutic opportunities2026
  2. 2Membrane Protein Glycosylation Revisited: Functional Dynamics and Emerging Clinical Insights2026 · 1 citations
  3. 3Novel glycan-related biomarker discovery by total glycomic and focused protein glycomic analyses2025
  4. 4The emerging role of glycoproteomics in cancer biomarker discovery2025
  5. 5The sweet symphony of N-glycans in myeloid malignancies2024 · 1 citations